INTRODUCTION
Mast cells are well known for their importance in host defence mechanisms. In particular, mast cells have been shown to play a central role in immediate hypersensitivity. Moreover, several reports suggest that mast cells participate in various inflammatory conditions such as rheumatoid arthritis (Bromley et al., 1984) , scleroderma (Hawkins et al., 1985) , wound repair (Wichmann, 1955) and thioglycollate-induced inflammation (Qureshi and Jakschik, 1988) . After activation by different mechanisms, such as cross-linking of IgE on the surface of the mast cells or exposure to anaphylatoxins C5a or C3a, the mast cells release their granular contents to the extracellular milieu. The mast-cell granules contain various mediators including histamine, proteoglycans, chemotactic factors, serine proteases and carboxypeptidases . The exact composition of the granules varies in different animal species. Furthermore, different subpopulations of mast cells within the same species contain different mediators. For instance, the major serine protease expressed by rat mast cells isolated from the gastrointestinal mucosa (mucosal mast cells) is a chymotrypsin-like enzyme termed rat mast-cell protease 2 (RMCP-2) (Benfey et al., 1987) , whereas the dominating serine protease synthesized by rat connective-tissue mast cells is a different chymotrypsin-like protease: rat mast-cell protease 1 (RMCP-1) (LeTrong et al., 1987) . Moreover, mucosal mast cells synthesize predominantly chondroitin sulphate proteoglycans (Enerback et al., 1985) , whereas heparin proteoglycan is the major proteoglycan species expressed by the connective-tissue mast cells .
The mast-cell secretory granule proteases constitute a large portion of the total protein content of the cells, suggesting an important role for these enzymes in the inflammatory response. However, despite the identification of several substrates for the mast-cell proteases (Reilly et al., 1982 (Reilly et al., , 1985 Schwartz et al., 1983 Schwartz et al., , 1985 DuBuske et al., 1984; Kokkonen et al., 1986; Mizutani et al., 1991) , the biological function of these enzymes inactivating activity displayed by the enzyme. When RMCP-1 was reconstituted with either endogenous [35S]heparin proteoglycans or standard pig mucosal heparin, the enzyme regained its thrombin-inactivating properties. Affinity chromatography of endogenous [35S]heparin on matrix-linked RMCP-1 demonstrated that all of the heparin molecules contained high-affinity binding sites for the mast-cell protease. In contrast, the endogenous mast-cell heparin showed low affinity for antithrombin, a protease inhibitor involved in the regulation of coagulation enzymes. remains to be determined. Inflammatory reactions are often characterized by extravascular fibrin deposition due to activation of the coagulation cascade by macrophages (Geczy, 1983) , and recent results indicate that mouse mast-cell proteases may participate in the down-regulation of the procoagulant activity expressed by macrophages: during our studies of macrophage prothrombinase activity (Lindahl et al., 1989) , expressed in cultures of mouse adherent peritoneal cells, we observed that thrombin, generated by the prothrombinase, was inactivated in the cell cultures (Pejler and Seljelid, 1992) . Subsequent purification of the thrombin-inactivating activity showed that the activity was associated with secretory granule chymase expressed by mast cells present in the cell cultures (Pejler and Karlstr6m, 1993) . In the present report the effect of rat peritoneal mast cells on thrombin was investigated. The mast cells were shown to rapidly inactivate thrombin. Purification of the thrombininactivating activity showed that the activity was associated with RMCP-1, complex-bound to heparin proteoglycan. Sterk and Ishizaka (1982) . Cells were seeded in 16-mm-diam. wells in Costar plastic dishes (Costar, Broadway, Cambridge, MA, U.S.A.; 2 x 105 cells/well in 0.4 ml of medium). The mast cells were cultured in Iscove's medium (Flow Laboratories) supplemented with BSA (0.4 mg/ml), human transferrin (1 jug/ml), gentamicin (Flow Laboratories; 100 ,tg/ml) and amphotericin (Flow Laboratories; 2.5 ,tg/ml). Incubations were conducted in a humified atmosphere of 5 % CO2 in air at 37 'C.
MATERIALS AND METHODS Reagents
Enzymic assays Assays for thrombin-inactivating activity in cell cultures were performed after addition of purified thrombin (0.5,tg) to the mast cells. Samples (50 ll) from spent media were collected at various time points. Aliquots (15 ll; duplicates) of the samples were transferred to 96-well microtitre plates and mixed with 200 1l of PBS. After addition of 20 ,ul of a solution of S-2238 (2.5 mM in H20), a chromogenic thrombin substrate, remaining thrombin activity was monitored with a Titertek Multiskan (Flow Laboratories) plate-reader.
For assessment of thrombin-inactivating activity in cellular extracts or in fractions eluted at different chromatographic steps, samples were, if necessary, diluted with 0.1 % Triton X-100 to yield a final NaCl concentration of 0.14 M. Aliquots (200, ul) of the diluted samples were transferred to 96-well microtitre plates. To each well was added 20 ng of thrombin. After incubation of the plates at 37 0C for appropriate times, 20 ,ul of the S-2238 solution (see above) was added to each well and residual thrombin activity was monitored. injected intraperitoneally with carrier-free 35SO42-(2 mCi/rat).
After 4 h the peritoneal cells were harvested, followed by purification of mast cells and subsequent purification of thrombin-inactivating activity as above. The N-terminal sequence of the purified protein was determined by adsorptive, biphasic column technology using a HP GI005 A protein sequenator (Hewlett-Packard protein chemistry system, Palo Alto, CA, U.S.A.). SDS/PAGE was performed according to the method of Laemmli (1970) . Briefly, samples were loaded on 20-cm-long gradient gels extending from 10 to 18 % (w/v) polyacrylamide. Electrophoresis was performed at 12 mA for approx. 18 h. After electrophoresis, gels were silver stained according to Morrissey (1981) .
Gel-filtration chromatography was carried out on a column (0.7 cm x 53 cm) of Sepharose CL-2B, equilibrated and eluted at approx. 1 ml/h with PBS/0.1 0% Triton X-100 containing 0.15 M or 2 M NaCl. Fractions (approx. 0.3 ml) were collected and were analysed for 35S radioactivity and chymotrypsin-like activity. Affinity chromatography on an antithrombin-Sepharose column was carried out according to Thunberg et al. (1982) using a column (3 ml) eluted with a linear salt gradient. Free glycosaminoglycan chains were prepared by fl-elimination of proteoglycans with 0.5 M NaOH for approx. 18 h (4 0C), followed by neutralization with 4 M HCl and dialysis against H20. HNO2 degradation (pH 1.5) of glycosaminoglycans was carried out as previously described (Pejler and David, 1987) .
Affinity chromatography on RMCP-1, coupled to activated CH-Sepharose 4B was performed on a column (approx. 1 ml) equilibrated with PBS/0.1 % Triton X-100. Samples of endogenous 35S-labelled heparin (approx. 500 c.p.m.) were applied to the column, followed by washing three times with 1 ml of equilibrating buffer. The column was then eluted stepwise with PBS/0.1 0% Triton X-100 containing 0.3 M, 0.5 M, 1 M, 2 M and 4 M NaCl, respectively (2 ml of each buffer). The eluted fractions Peritoneal mast cells were purified from two rats. Cells were were subsequently analysed for 31 S radioactivity. Extracts from mast cells, purified from rats that had been injected intraperitoneally with 35so42-(2 mCi/rat), were applied to a column of DEAE-Sephacel. Eluted fractions were analysed for thrombin-inactivating activity (0), chymotrypsin-like activity (-)and for 35S radioactivity (U).
---, NaCI concentration. levels ofthrombin-inactivating activity (approx. 4 ,ug of thrombin inactivated/h per 1 x 106 cells; medium conditioned for 1 h by the mast cells) (Figure 1 ). Ultracentrifugation (100000 g, 1 h) of the thrombin-inactivating activity recovered in the conditioned medium reduced the activity by approx. 80 %, indicating that the thrombin-inactivating activity was released from the mast cells in a particulate form (not shown). Incubation of the mast cells (Figure 1 ) or the conditioned medium (results not shown) with the polycation Polybrene (10 ,ug) completely abolished the thrombin-inactivating activity. Addition of 1251-thrombin to the mast-cell cultures, followed by SDS/PAGE and autoradiographic analysis of spent media recovered after various times showed that thrombin was degraded into distinct proteolytic fragments with molecular masses of approx. 27 kDa and 15 kDa respectively (G. Pejler and K. Soderstr6m, unpublished work).
Purification of the thrombin-inactivating activity
Initial experiments showed that the thrombin-inactivating activity could be recovered after treatment of the mast cells with Triton X-100. However, to obtain solubilization of the activity, the buffers had to be supplemented with NaCl at concentrations above 0.5 M (results not shown). For purification of the thrombin-inactivating activity, mast cells were solubilized with PBS supplemented with 1 % Triton X-100 and 2 M NaCl.
The inhibition of the thrombin-inactivating activity by the polycation Polybrene (Figure 1) suggested that the activity exhibited a negative net charge. Therefore, the mast-cell extracts were applied to a DEAE-Sephacel anion-exchange column eluted with a salt gradient. The thrombin-inactivating activity bound strongly to the column and was eluted at a NaCl concentration of approx. 0.8 M (Figure 2) . For further purification, the thrombin-inactivating activity was applied to a column of Superdex 75 and eluted with PBS/0.1 % Triton X-100/2 M NaCl. The thrombin-inactivating activity was eluted from the column as one major peak along with a minor, slightly retarded, peak (Figure 3b ). To detect thrombin-inactivating activity, 0.1 ,ug/ml heparin was added to the fractions which were eluted from the column (see below). Fractions were pooled as indicated in the figure by bars and were analysed by SDS/PAGE. Fractions containing thrombin-inactivating activity demonstrated the presence of a single band of molecular mass 29 kDa. The 29 kDa band was absent in fractions devoid of activity (Figure 3c ). After Superdex 75 chromatography the thrombin-inactivating activity had been purified approx. 25-fold from the mast-cell extracts, with a yield of approx. 20 %.
The purified thrombin-inactivating activity was subjected to N-terminal sequence analysis. The obtained sequence, Ile-IleGly-Gly-Val-Glu-Ser-Arg-Pro-His-Ser-Arg-Pro-Tyr-Met-AlaHis-Leu-Glu-Ile-, demonstrated 100% identity with RMCP-1 (LeTrong et al., 1987) . Incubation of the purified thrombininactivating activity with [3H]di-isopropyl fluorophosphate, followed by SDS/PAGE and autoradiography showed incorporation of radioactivity into the 29 kDa band (results not shown). Incubation of the purified protease with thrombin resulted in degradation of thrombin into proteolytic fragments with molecular masses of 27 kDa and 15 kDa respectively (G. Pejler, A. Karlstr6m and L. Berg, unpublished work) .
RMCP-1 has been shown to display chymotrypsin-like substrate specificity and is consequently termed a 'chymase'. Experiments were thus conducted to assess if the thrombininactivating activity co-eluted with chymotrypsin-like activity. Chymotrypsin-like activity was measured utilizing the chromogenic chymotrypsin substrate S-2586. The thrombin-inactivating activity and the chymotrypsin-like activity were indeed shown to 
Interaction of RMCP-1 with heparin
The mast-cell proteases are stored in the secretory granules together with negatively charged, sulphated heparin or chondroitin sulphate proteoglycans. To determine if RMCP-1 was recovered as a complex with proteoglycans, rats were injected intraperitoneally with 35SO42-, followed by purification of RMCP-1 as described above. The 35S radioactivity showed codistribution with both thrombin-inactivating activity and chymotrypsin-like activity on anion-exchange chromatography (Figure 2 ). When the material, after purification by anionexchange chromatography, was analysed by Superdex 75 chromatography in low salt conditions (PBS/0.1 % Triton X-100), the thrombin-inactivating activity, chymotrypsin-like activity and 35S radioactivity showed co-distribution (Figure 3a) .
Figure 4 Gel filtration of RMCP-1
A sample of RMCP-1 (corresponding to approx. 5 units of thrombin-inactivating activity), puritied by anion-exchange chromatography from mast cells that were labelled in vivo with 35s042-(see Figure 2) , was applied to a column of Sepharose CL-2B. The column was equilibrated and eluted with either PBS/0.1 % Triton X-100 (a) or PBS/0.1 % Triton X-100/2 M NaCI (b). Fractions (approx. 0.3 ml) were collected and analysed for chymotrypsin-like activity (0) and for 35S radioactivity (0).
In contrast, when the column was eluted in high salt conditions (PBS/0.1 % Triton X-100/2 M NaCl), the 35S radioactivity was completely separated from the thrombin-inactivating activity and chymotrypsin-like activity (Figure 3b ). To determine the nature of the recovered 35S-labelled material, 35S radioactivity obtained after high-salt chromatography (see Figure 3b ) was pooled, dialysed against H20, evaporated to dryness and treated with HNO2 at pH 1.5. The HNO2 treatment achieves degradation of heparin-like polysaccharides, whereas chondroitin sulphate is not affected. Superdex 75 chromatography of the HNO2-treated 35S radioactivity showed that approx. 95 % of the material was degraded into, predominantly, disaccharides, indicating that it was heparin (results not shown). To determine whether the mast-cell heparin was present as proteoglycans or as free polysaccharide chains, the 35S-labelled material was treated with alkali (see the Materials and methods section) followed by gel filtration on a Superose 6 column. The alkali treatment, known to release glycosaminoglycan chains from the protein core ofproteoglycans, yielded a marked decrease in size of the 35S-labelled material, demonstrating that the mastcell heparin was present as a proteoglycan (results not shown). The [35S]heparin chains were considerably larger in size than standard pig mucosal heparin (not shown).
To obtain evidence for complex formation between the heparin proteoglycan and RMCP-1, material purified by anion-exchange chromatography was subjected to gel filtration on a Sepharose CL-2B column. On chromatography in low salt (PBS/0. 1% Triton X-100), RMCP-l (Figure 3 ). As RMCP-1 is dissociated kbatiotnof R(bMCd) of th from heparin proteoglycans at 2 M NaCl (Figure 3b ), experiments were conducted to determine whether heparin was important for the activity of the enzyme. Purified RMCP-1 was incubated with either standard pig mucosal heparin or endogenous 35S-labelled mast-cell heparin proteoglycans (recovered after Superdex 75 chromatography in 2 M NaCl; see Figure 3b ), followed by assessment of the thrombin-inactivating activity of the enzyme. As a comparison, the effect of heparin on the direct cleavage of a chromogenic chymotrypsin substrate (S-2586) by RMCP-l (chymotrypsin-like activity) was determined. Both pig mucosal ( Figure 5a ) and endogenous heparin (Figure 5c ) strongly potentiated the thrombin-inactivating activity of RMCP-1. Optimal stimulation (up to 9-fold) of the thrombin-inactivating activity occurred at approx. 0.1 utg/ml of standard heparin. At higher heparin concentrations, a marked decrease in the potentiation was observed. In contrast, the S-2586-cleaving activity of RMCP-l showed only approx. 2-fold maximal stimulation by standard (Figure 5b ) or endogenous ( Figure Sd) heparin.
100
Control experiments showed that heparin had no effect on thrombin in the absence of RMCP-l (results not shown). Experiments were conducted to compare the thrombin-I , antithrombin and inactivating activities of RMCP-l and antithrombin ( Figure 6 ). showed that essentially all of the proteoglycans and the heparin chains bound strongly to the column, and that most of the material was eluted at NaCl concentrations between 0.5 and 1 M NaCl (Table 1) Schechter et al., 1986) as well as a carboxypeptidase (Reynolds et al., 1989) . Mouse mast cells express, in addition to a carboxypeptidase (Serafin et al., 1987) , seven different secretory granule serine proteases termed murine mastcell proteases 1-7 (MMCP-1-7) (Reynolds et al., 1990; Huang et al., 1991; McNeil et al., 1992) of which MMCP-1-5 are chymases and MMCP-6 and 7 are tryptases. In rats, two different mast-cell chymases, RMCP-1 and RMCP-2 have been identified (Benfey et al., 1987; LeTrong et al., 1987) along with a tryptase (Kido et al., 1985) and a carboxypeptidase (Everitt and Neurath, 1980 (Geczy, 1983; Lindahl et al., 1989) . Thrombin, generated by the macrophage prothrombinase, displays, in addition to its procoagulant activity, a wide spectrum of activities of potential importance in an inflammatory reaction. Thrombin is a potent chemotactic factor for leucocytes (Bar-Shavit et al., 1983) , induces proliferation of various cell types (Carney and Cunningham, 1978; Clohisy et al., 1990) , elicits degranulation of mast cells (Razin et al., 1985) and induces the expression of neutrophil adhesion molecules on the surface of endothelial cells (Hattori et al., 1989) . Thus, the inactivation of thrombin by RMCP-1 may be ofphysiological significance by down-regulating the thrombin that is generated by the macrophage prothrombinase, thereby restricting the procoagulant and proinflammatory activities of the coagulation enzyme. In a recent report we showed that mouse mast-cell chymases (MMCP-3 or -4) also had thrombin-inactivating properties (Pejler and Karlstr6m, 1993 ). RMCP-1 shows a high degree of structural similarity with MMCP-4 (88% identity; Huang et al., 1991) and is thought to be the rat counterpart of the mouse protease. Apparently, RMCP-1 and the corresponding mouse enzymes also share certain functional properties.
The mast-cell proteases generally carry net positive charges (Huang et al., 1991) Woodbury et al., 1981; Gibson and Miller, 1986) .
After dissociation from the heparin proteoglycan, RMCP-1 showed a marked loss of thrombin-inactivating activity. How (1977) reported that heparin partly masked the active site of rat chymase. Heparin was later demonstrated to stabilize human lung mast-cell tryptase into an active tetramer (Schwartz and Bradford, 1986) , and was shown to alter the substrate specificity of the tryptase (Schwartz et al., 1983) . Sayama et al. (1987) reported that heparin decreased the activity of human chymase by sterically hindering large substrates from entering the active site. Further, heparin has been shown to be important for the fibrinogenolytic activity of human tryptase (Schwartz et al., 1985) and for the degradation of anaphylatoxin C3a by rat mast-cell chymase (Gervasoni et al., 1986) . It is clear that more work is required to understand fully the functional significance of the interaction between heparin and the mast-cell proteases.
In an attempt to characterize further the interaction between heparin and RMCP-1, endogenous 35S-labelled mast-cell heparin was subjected to affinity chromatography on matrix-linked RMCP-1. The results showed that virtually all of the heparin proteoglycans and all of the free heparin chains, released by alkali treatment of intact proteoglycans, contained high-affinity binding sites for RMCP-1. Further work will be required to determine if heparin is bound to RMCP-1 through unspecific electrostatic interactions, or if the binding is mediated by a specific saccharide sequence. Such specific interactions have been identified for the interaction between heparin and the protease inhibitor antithrombin (Bourn and Lindahl, 1993) , and in the binding of heparan sulphate (a heparin-like glycosaminoglycan) to basic fibroblast growth factor (Habuchi et al., 1992) .
Heparin is well known for its anticoagulant activity, mediated by antithrombin, which in the presence of heparin inactivates various proteases of the coagulation cascade (e.g. Factor Xa, thrombin; Bourn and Lindahl, 1993) . Affinity chromatography of heparin on antithrombin-Sepharose has shown that commercial heparin preparations can be separated into two populations: heparin with low affinity for antithrombin showing low anticoagulant activity and heparin with high affinity for antithrombin displaying high anticoagulant activity (Ho6k et al., 1976) . In the present investigation it was shown that most of the heparin isolated after in vivo-labelling of the peritoneal mast cells with 35SO42-, showed low affinity for antithrombin, suggesting that it is not involved in the regulation of coagulation enzymes. Instead, the tight association of heparin with RMCP-1, with consequent activation of the enzyme, suggests that the physiological function of rat peritoneal mast-cell heparin involves interaction with the mast-cell proteases.
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